Predictive factors associated with pemetrexed acute toxicity
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: Pemetrexed has shown efficacy as monotherapy or in combination with platinum salts in the treatment of non-small cell lung cancer and mesothelioma. However, severe hematological toxicities induced by pemetrexed-based chemotherapy have been observed. Some studies have suggested that drug interactions may be associated with pemetrexed toxicity. The objective of this study was to determine predictive factors, including drug interactions, associated with pemetrexed toxicity.
METHODS: This retrospective open monocentric study included patients consecutively treated with pemetrexed after a multidisciplinary risk assessment. Patients who experienced toxicity of grade 3 or 4 according to the Common Terminology Criteria for Adverse Events v5.0, or a grade 2 leading to a change in management, during the first four courses of pemetrexed, were assigned to the early limiting toxicities (ELT) group. Univariate and multivariable logistic regression models were used to test the association variables with the occurrence of ELT.
RESULTS: Seventy-four patients were included in this study (median age: 67 years, with non-small cell lung cancer adenocarcinoma (88%), mesothelioma (7%), or others (5%). Thirty-six patients (49%) were assigned to the ELT group (27 grades 3 and 4; 9 grade 2 with management modification). Three baseline factors were associated with pemetrexed ELT in univariate and multivariate analysis: cystatin clearance (p = 0.0135), albumin level (p = 0.0333), and proton pump inhibitors use (p = 0.035).
CONCLUSION: To conclude, ELT induced by pemetrexed-based treatments occur frequently in cancer patients in a real-world setting. A pretherapeutic assessment before pemetrexed initiation should include three major checkpoints: use of proton pump inhibitors, sarcopenia, and denutrition evaluation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
European journal of clinical pharmacology - 79(2023), 5 vom: 06. Mai, Seite 635-641 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bonnet, Mathilde [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04Q9AIZ7NO |
|---|
| Anmerkungen: |
Date Completed 19.04.2023 Date Revised 19.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00228-023-03478-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354571400 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354571400 | ||
| 003 | DE-627 | ||
| 005 | 20231226062519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00228-023-03478-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354571400 | ||
| 035 | |a (NLM)36951965 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bonnet, Mathilde |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predictive factors associated with pemetrexed acute toxicity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2023 | ||
| 500 | |a Date Revised 19.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a PURPOSE: Pemetrexed has shown efficacy as monotherapy or in combination with platinum salts in the treatment of non-small cell lung cancer and mesothelioma. However, severe hematological toxicities induced by pemetrexed-based chemotherapy have been observed. Some studies have suggested that drug interactions may be associated with pemetrexed toxicity. The objective of this study was to determine predictive factors, including drug interactions, associated with pemetrexed toxicity | ||
| 520 | |a METHODS: This retrospective open monocentric study included patients consecutively treated with pemetrexed after a multidisciplinary risk assessment. Patients who experienced toxicity of grade 3 or 4 according to the Common Terminology Criteria for Adverse Events v5.0, or a grade 2 leading to a change in management, during the first four courses of pemetrexed, were assigned to the early limiting toxicities (ELT) group. Univariate and multivariable logistic regression models were used to test the association variables with the occurrence of ELT | ||
| 520 | |a RESULTS: Seventy-four patients were included in this study (median age: 67 years, with non-small cell lung cancer adenocarcinoma (88%), mesothelioma (7%), or others (5%). Thirty-six patients (49%) were assigned to the ELT group (27 grades 3 and 4; 9 grade 2 with management modification). Three baseline factors were associated with pemetrexed ELT in univariate and multivariate analysis: cystatin clearance (p = 0.0135), albumin level (p = 0.0333), and proton pump inhibitors use (p = 0.035) | ||
| 520 | |a CONCLUSION: To conclude, ELT induced by pemetrexed-based treatments occur frequently in cancer patients in a real-world setting. A pretherapeutic assessment before pemetrexed initiation should include three major checkpoints: use of proton pump inhibitors, sarcopenia, and denutrition evaluation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Albumin | |
| 650 | 4 | |a Pemetrexed | |
| 650 | 4 | |a Proton pump inhibitors | |
| 650 | 4 | |a Sarcopenia | |
| 650 | 4 | |a Toxicity | |
| 650 | 7 | |a Pemetrexed |2 NLM | |
| 650 | 7 | |a 04Q9AIZ7NO |2 NLM | |
| 650 | 7 | |a Proton Pump Inhibitors |2 NLM | |
| 700 | 1 | |a Jouinot, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Boudou-Rouquette, Pascaline |e verfasserin |4 aut | |
| 700 | 1 | |a Seif, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Villeminey, Clémentine |e verfasserin |4 aut | |
| 700 | 1 | |a Arrondeau, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Vidal, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Batista, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Wislez, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Blanchet, Benoit |e verfasserin |4 aut | |
| 700 | 1 | |a Goldwasser, François |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas-Schoemann, Audrey |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical pharmacology |d 1971 |g 79(2023), 5 vom: 06. Mai, Seite 635-641 |w (DE-627)NLM000099538 |x 1432-1041 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2023 |g number:5 |g day:06 |g month:05 |g pages:635-641 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00228-023-03478-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2023 |e 5 |b 06 |c 05 |h 635-641 | ||